- Home
- SYM vs PTGX Comparison
SYM vs PTGX Comparison
Compare SYM & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SYM | PTGX |
|---|---|---|
| Founded | 2005 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4B | 5.2B |
| IPO Year | 2021 | 2016 |
Fundamental Metrics
Financial Performance| Metric | SYM | PTGX |
|---|---|---|
| Price | $49.60 | $98.12 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 13 | 12 |
| Target Price | $57.46 | ★ $106.67 |
| AVG Volume (30 Days) | ★ 1.1M | 709.8K |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $2,246,922,000.00 | N/A |
| Revenue This Year | $24.75 | $867.86 |
| Revenue Next Year | $27.90 | N/A |
| P/E Ratio | $2,564.50 | ★ N/A |
| Revenue Growth | ★ 25.65 | N/A |
| 52 Week Low | $16.32 | $39.60 |
| 52 Week High | $87.88 | $105.69 |
Technical Indicators
Market Signals| Indicator | SYM | PTGX |
|---|---|---|
| Relative Strength Index (RSI) | 42.14 | 62.54 |
| Support Level | $47.71 | $76.63 |
| Resistance Level | $64.35 | N/A |
| Average True Range (ATR) | 2.60 | 4.83 |
| MACD | 0.17 | 0.45 |
| Stochastic Oscillator | 44.35 | 61.78 |
Price Performance
Historical ComparisonAbout SYM Symbotic Inc.
Symbotic Inc. is an automation technology company that develops solutions to improve operating efficiencies in modern warehouses. The group designs, commercializes, and deploys end-to-end technology systems that significantly enhance supply chain operations. The company automates the processing of pallets, cases, and individual items within warehouse environments. Its systems strengthen operations at the front end of the supply chain and provide benefits to all supply partners downstream. The company operates in two geographical regions: the United States and international markets, with the majority of its revenue generated in the United States.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.